🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million new cases annually. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the face of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization represents a major breakthrough in the therapy of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Data and Worldwide Availability

Based on results released by a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The research included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have shared positive views. The availability of a single-dose, oral treatment such as this is hailed as a "revolutionary step" for public health efforts. This is deemed crucial to lessen the impact of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea globally.